This Accenture survey explores how pharmaceutical companies can better engage with healthcare providers (HCPs) in a post-COVID-19 landscape.
The study, involving 720 HCPs across six countries, reveals that while pharma has improved its communication, there's still a significant gap in understanding HCPs' evolving needs and those of their patients.
A key finding is that HCPs reward companies that demonstrate this understanding with more time and attention, particularly as many now have fewer patient visits.
Ultimately, HCPs highly value meaningful connections that blend virtual and in-person interactions, prioritising content that directly aids patient care and decision-making, such as data-driven recommendations.